Publications

1. GVS advice on lanadelumab (Takhzyro®) for the prevention of recurrent attacks of hereditary angioedema (HAE)

   The National Health Care Institute has assessed whether the medicinal product lanadelumab (Takhzyro®) can be included in the ...

   Report | 28-04-2023

2. GVS advice on sacubitril/valsartan (Entresto®)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute has carried out an ...

   Report | 28-04-2023

3. Package advice on the lock procedure medicinal product brexucabtagene autoleucel (Tecartus®) for the treatment of mantle cell lymphoma (MCL)

   The National Health Care Institute has assessed whether the medicinal product brexucabtagene autoleucel (Tecartus®) can be ...

   Report | 17-04-2023

4. GVS advice for the extension of the List 2 conditions for evolocumab (Repatha®) and alirocumab (Praluent®) for excessively high cholesterol

   The National Health Care Institute has assessed whether the PCSK9 inhibitors evolocumab (Repatha®) and alirocumab (Praluent®) can ...

   Report | 17-04-2023

5. GVS advice on mifepristone (Mifegyne®) for the treatment of miscarriages

   The National Health Care Institute has tested whether mifepristone (Mifegyne®) can be included in the Medicine Reimbursement ...

   Report | 08-03-2023

6. Conditional inclusion of orphan drugs, conditionals and exceptionals (progress report for 2022)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

   Report | 01-03-2023

7. Package advice on the lock procedure medicinal product trastuzumab-deruxtecan (Enhertu®) for the treatment of HER2-positive breast cancer

   The National Health Care Institute has assessed whether the medicinal product trastuzumab-deruxtecan (Enhertu®) can be reimbursed ...

   Publication | 15-02-2023

8. GVS advice icosapent-ethyl (Vazkepa®)

   The National Health Care Institute has completed its assessment whether the product icosapent-ethyl (Vazkepa®) can be included in ...

   Report | 15-02-2023

9. Package advice on the lock procedure medicinal product tafasitamab (Minjuvi®) for the treatment of lymphoma

   The National Health Care Institute has assessed whether the medicinal product tafasitamab (Minjuvi®) can be reimbursed from the ...

   Report | 15-02-2023

10. GVS advice patiromer (Veltassa®) cancellation List 2 conditions

    The Minister of Health, Welfare and Sport (VWS) has adopted the recommendation of the National Health Care Institute. This means ...

    Report | 01-02-2023